載入...
Tβ4–Ac-SDKP pathway: Any relevance for the cardiovascular system?
The last 20 years witnessed the emergence of the thymosin β4 (Tβ4)–N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) pathway as a new source of future therapeutic tools to treat cardiovascular and renal diseases. In this review article, we attempted to shed light on the numerous experimental findings...
Na minha lista:
| 發表在: | Can J Physiol Pharmacol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6824425/ https://ncbi.nlm.nih.gov/pubmed/30854877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1139/cjpp-2018-0570 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|